Carregant...
An update on the role of daratumumab in the treatment of multiple myeloma
Monoclonal antibodies (mAbs) have emerged as a promising new drug class for the treatment of multiple myeloma (MM). Daratumumab (DARA), a CD38 mAb, has demonstrated safety, tolerability and activity in a range of clinical trials, both as monotherapy and in combination strategies for MM. The favorabl...
Guardat en:
| Publicat a: | Ther Adv Hematol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5167079/ https://ncbi.nlm.nih.gov/pubmed/28042457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716677523 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|